The most common grade 3 or higher adverse events during the combination phase were neutropenia ( in 35 [ 43 % ] of 81 patients in the olaparib plus chemotherapy group vs 26 [ 35 % ] of 75 in the chemotherapy alone group ) and anaemia ( seven [ 9 % ] vs five [ 7 % ] ) .